October 14, 2020
Features
40
10
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
October 14, 2020
Features
40
10
How ramped-up support and educational services have helped bridge the chasms and ease fears along the patient care continuum.
October 14, 2020
Features
40
10
Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
October 14, 2020
Columns
40
10
Missteps threaten agency’s independence as vaccines seek finish line.
October 14, 2020
Features
40
10
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
October 14, 2020
Columns
40
10
Tips for rounding out the rough edges in crossover.
October 14, 2020
Features
40
10
The role of advanced data technologies in reducing hurdles.
October 14, 2020
Columns
40
10
Report sets out self-assessment measures for low- and middle-income countries in their adoption of new health technologies.
October 14, 2020
Issue PDF
40
10
Click the title above for a link to open the Pharmaceutical Executive October 2020 issue in an interactive PDF format.
October 14, 2020
Features
40
10
Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch
October 14, 2020
From the Editor
40
10
Previewing executive trends thought of by leaders in the pharma industry.
October 14, 2020
Columns
40
10
Universal strategy push elicits range of constituency views.
October 14, 2020
Columns
40
10
Biopharma must find sustainable models for public policy engagement.